Breakthrough Therapy Designation was based on results from the Phase I/II RAINFOL-01 trial, which showed encouraging clinical ...

Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), and Kyle McAllister, co-founder, CEO, Trially, ...

Strategic AI applications are helping life sciences teams overcome hidden bias, accelerate data discovery, and improve ...

Ampreloxetine is being developed to address the root cause of blood pressure instability in multiple system atrophy, aiming ...

The Supreme Court has ruled 5-4 to allow the Trump administration’s NIH funding cuts to continue, impacting more than 1,700 ...

A new exploratory study will evaluate the safety of Anktiva in patients with long COVID, with secondary and exploratory ...

In this episode of the Applied Clinical Trials Brief, we recap our three most-viewed stories of the week—covering the Supreme Court’s decision to uphold NIH funding cuts tied to DEI, Phase II data ...

Results from the first part of a Phase I/II trial (NCT06569823) showed that Z-1018 generated immune responses comparable to ...

This explainer unpacks how recent US policy shifts are reshaping diversity, equity, and inclusion in clinical research, ...

Results from the Phase II OptiTROP-Lung01 trial (NCT05351788) showed that Sichuan Kelun-Biotech’s sac-TMT combined with ...

In this video interview, Caroline Potts, general manager of sites and patient services at Medical Research Network (MRN), ...

In this video interview, Caroline Potts, general manager of sites and patient services at Medical Research Network (MRN), ...